Hansoh Pharmaceutical Group Announces Acceptance of New Drug Application for Dalmelitinib Mesylate Tablets by NMPA

Key Highlights

• Hansoh Pharmaceutical Group Company Limited has announced that the New Drug Application (NDA) for its innovative drug, Dalmelitinib Mesylate Tablets, in combination with Aumolertinib Mesylate Tablets (Ameile®), has been accepted by the National Medical Products Administration (NMPA) of China.
• The NDA acceptance is specifically for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) whose tumors exhibit mesenchymal to epithelial transition factor (MET) amplification following prior EGFR tyrosine kinase inhibitor (TKI) therapy.
• Dalmelitinib Mesylate Tablets (HS-10241) is a highly selective, orally administered c-MET TKI developed in-house by Hansoh, marking a significant milestone in the company’s innovation pipeline.

Details of the Announcement

The acceptance of the NDA by the NMPA represents a major regulatory milestone for Hansoh Pharmaceutical. The drug targets a significant unmet medical need in the area of lung cancer, specifically for patients whose disease has progressed after earlier targeted therapies. The combination therapy is expected to provide a new treatment option for a patient population with limited alternatives.

This announcement signals Hansoh’s continued commitment to developing cutting-edge oncology therapies and reinforces its position as a leader in pharmaceutical innovation in China. The in-house development of Dalmelitinib, a highly selective MET inhibitor, highlights the Group’s research and development capabilities and potential for future growth in the oncology market.

The acceptance of this NDA could lead to future commercialization, subject to final regulatory approval, which may have a positive impact on the company’s revenues and share value. Investors should note that successful approval and market launch of Dalmelitinib Mesylate Tablets could strengthen Hansoh’s oncology portfolio and competitive positioning in the Chinese pharmaceutical sector.

The Board of Hansoh Pharmaceutical Group is led by Chairlady Zhong Huijuan, with an experienced team of executive and independent non-executive directors, underscoring the company’s strong governance and leadership.

Potential Price Sensitive Information for Shareholders

• Regulatory Progress: NDA acceptance is a critical step towards commercialization and could drive share price appreciation if the drug is approved and launches successfully.
• Market Opportunity: The targeted patient population (EGFR mutation-positive NSCLC with MET amplification post-TKI therapy) represents a high unmet need, providing potential for strong market uptake.
• Innovation and Pipeline: The self-developed nature of Dalmelitinib Mesylate Tablets demonstrates Hansoh’s R&D strength and may signal further pipeline opportunities, which are closely watched by investors.
• Leadership and Governance: The announcement confirms the presence of a capable executive and independent director team, which is reassuring for shareholders.

Conclusion

This NDA acceptance is a noteworthy development for Hansoh Pharmaceutical, potentially laying the foundation for enhanced revenue streams and improved market position in China’s oncology sector. Investors should monitor subsequent regulatory updates, clinical data, and commercialization progress, as these will be crucial drivers of share value and company growth.

Disclaimer

The information provided in this article is for informational purposes only and should not be construed as investment advice. Investors are advised to conduct their own research and consult professional advisors before making any investment decisions. No liability is accepted for any loss or damage arising from reliance on the information contained herein.

View HANSOH PHARMA Historical chart here